HLB Life Science Co., Ltd. (KOSDAQ:067630)

Market Cap	800.37B
Revenue (ttm)	102.24B
Net Income (ttm)	6.14B
Shares Out	121.82M
EPS (ttm)	54.00
PE Ratio	121.67
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,279,943
Average Volume	1,873,351
Open	6,970.00
Previous Close	6,770.00
Day's Range	6,550.00 - 6,970.00
52-Week Range	5,990.00 - 20,500.00
Beta	-0.15
RSI	29.76
Earnings Date	Mar 19, 2025

About HLB Life Science

HLB Life Science Co., Ltd. develops and manufactures in vitro diagnostic medical devices and quasi-drugs in South Korea and internationally. It also develops Rivoceranib, a small-molecule tyrosine kinase inhibitor for the treatment of various cancers, including gastric cancer, colon cancer, hepatocellular carcinoma, non-small cell lung cancer, breast cancer, mesothelioma, renal cell carcinoma, and neuroendocrine tumors; and Pyrotinib, an anticancer drug that inhibits the proliferation, division, and survival of cancer cells. In addition, the co...

• Industry: Utilities - Renewable
• Sector: Utilities
• Founded: 1998
• Employees: 145
• Stock Exchange: KOSDAQ
• Ticker Symbol: 067630

Financial Performance

In 2023, HLB Life Science's revenue was 97.99 billion, a decrease of -1.61% compared to the previous year's 99.59 billion. Losses were -5.98 billion, -88.98% less than in 2022.